(Q43274035)

English

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

scientific article published on 18 September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 November 2017

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study (English)

1 reference

Europe PubMed Central

18 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

18 November 2017

19

1 reference

Europe PubMed Central

18 November 2017

Maciej Krzakowski

5

object named as

Maciej Krzakowski

1 reference

Europe PubMed Central

18 November 2017

author name string

Tudor Ciuleanu

1

1 reference

Europe PubMed Central

18 November 2017

Thomas Brodowicz

2

1 reference

Europe PubMed Central

18 November 2017

Christoph Zielinski

3

1 reference

Europe PubMed Central

18 November 2017

Joo Hang Kim

4

1 reference

Europe PubMed Central

18 November 2017

Eckart Laack

6

1 reference

Europe PubMed Central

18 November 2017

Isabel Bover

8

1 reference

Europe PubMed Central

18 November 2017

Stephen Begbie

9

1 reference

Europe PubMed Central

18 November 2017

Valentina Tzekova

10

1 reference

Europe PubMed Central

18 November 2017

Branka Cucevic

11

1 reference

Europe PubMed Central

18 November 2017

Jose Rodrigues Pereira

12

1 reference

Europe PubMed Central

18 November 2017

Sung Hyun Yang

13

1 reference

Europe PubMed Central

18 November 2017

Jayaprakash Madhavan

14

1 reference

Europe PubMed Central

18 November 2017

Katherine P Sugarman

15

1 reference

Europe PubMed Central

18 November 2017

Patrick Peterson

16

1 reference

Europe PubMed Central

18 November 2017

William J John

17

1 reference

Europe PubMed Central

18 November 2017

Kurt Krejcy

18

1 reference

Europe PubMed Central

18 November 2017

language of work or name

0 references

publication date

18 September 2009

1 reference

Europe PubMed Central

18 November 2017

1 reference

Europe PubMed Central

18 November 2017

374

1 reference

Europe PubMed Central

18 November 2017

1432-1440

1 reference

Europe PubMed Central

18 November 2017

9699

1 reference

Europe PubMed Central

18 November 2017

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimizing first-line treatment options for patients with advanced NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapeutic management of stage IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961497-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)61497-5

1 reference

Europe PubMed Central

18 November 2017

1 reference

Europe PubMed Central

18 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43274035&oldid=1985276494"